Proteolytic activity of contact factor zymogens.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
02 2021
Historique:
received: 24 08 2020
revised: 16 10 2020
accepted: 22 10 2020
pubmed: 28 10 2020
medline: 15 5 2021
entrez: 27 10 2020
Statut: ppublish

Résumé

Contact activation is triggered when blood is exposed to compounds or "surfaces" that promote conversion of the plasma zymogens factor XII (FXII) and prekallikrein to the active proteases FXIIa and kallikrein. FXIIa promotes blood coagulation by converting zymogen factor XI (FXI) to the protease FXIa. Contact activation appears to represent an enhancement of the propensity for FXII and prekallikrein to reciprocally activate each other by surface-independent limited proteolysis. The nature of the activities that perpetuate this process, and that trigger contact activation, are debated. FXII and prekallikrein, like most members of the chymotrypsin/trypsin protease family, are synthesized as single polypeptides that are presumed to be in an inactive state. Internal cleavage leads to conformational changes in the protease domain that convert the enzyme active site from a closed conformation to an open conformation accessible to substrates. We observed that FXII expresses a low level of activity as a single-chain zymogen that catalyzes prekallikrein activation in solution, as well as surface-dependent activation of prekallikrein, FXI, and FXII (autoactivation). Prekallikrein also expresses activity that promotes cleavage of kininogen to release bradykinin, and surface-dependent FXII activation. Modeling suggests that a glutamine residue at position 156 in the FXII and prekallikrein protease domains stabilizes an open active site conformation by forming hydrogen bonds with Asp194. The activity inherent in FXII and prekallikrein suggests a mechanism for sustaining reciprocal activation of the proteins and for initiating contact activation, and supports the premise that zymogens of some trypsin-like enzymes are active proteases.

Identifiants

pubmed: 33107140
doi: 10.1111/jth.15149
pmc: PMC8552315
mid: NIHMS1748235
pii: S1538-7836(22)00644-4
doi:

Substances chimiques

Enzyme Precursors 0
Factor XII 9001-30-3
Factor XI 9013-55-2
Prekallikrein 9055-02-1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

330-341

Subventions

Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States
Organisme : British Heart Foundation
ID : RG/12/9/29775
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : HL140025
Pays : United States

Informations de copyright

© 2020 International Society on Thrombosis and Haemostasis.

Références

Proc Natl Acad Sci U S A. 1976 Aug;73(8):2554-8
pubmed: 1066663
Proc Natl Acad Sci U S A. 1978 Apr;75(4):1998-2002
pubmed: 273926
Biochemistry. 1991 Feb 26;30(8):2050-6
pubmed: 1998666
Thromb Haemost. 2007 Jul;98(1):77-83
pubmed: 17597995
Curr Opin Hematol. 2016 Sep;23(5):453-61
pubmed: 27380559
J Allergy Clin Immunol. 2009 Jul;124(1):143-9
pubmed: 19342086
J Biol Chem. 2001 Mar 2;276(9):6616-20
pubmed: 11078728
J Biol Chem. 1993 May 15;268(14):10024-8
pubmed: 7683665
Int J Lab Hematol. 2014 Jun;36(3):374-81
pubmed: 24750684
Blood Adv. 2019 Feb 26;3(4):658-669
pubmed: 30808684
Biochemistry. 1987 Jan 27;26(2):338-43
pubmed: 3103680
Chem Rev. 2002 Dec;102(12):4501-24
pubmed: 12475199
Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6388-93
pubmed: 17405864
J Biol Chem. 2013 Apr 19;288(16):11601-10
pubmed: 23467412
Blood Coagul Fibrinolysis. 1995 Jun;6 Suppl 1:S14-9
pubmed: 7647216
J Thromb Haemost. 2018 Sep;16(9):1674-1685
pubmed: 29920929
Semin Thromb Hemost. 1976 Jul;3(1):1-26
pubmed: 139682
J Clin Invest. 1983 Jan;71(1):149-58
pubmed: 6184384
J Thromb Haemost. 2016 Jan;14(1):28-39
pubmed: 26565070
Curr Opin Hematol. 2018 Sep;25(5):389-394
pubmed: 30028742
Blood. 2019 Mar 7;133(10):1152-1163
pubmed: 30591525
Blood. 2020 Feb 20;135(8):558-567
pubmed: 31800958
Cell. 2009 Dec 11;139(6):1143-56
pubmed: 20005807
Nat Struct Mol Biol. 2006 Jun;13(6):557-8
pubmed: 16699514
Thromb Res. 2018 Jan;161:94-105
pubmed: 29223926
J Clin Invest. 2008 Sep;118(9):3208-18
pubmed: 18725990
Acta Physiol (Oxf). 2012 Dec;206(4):215-9
pubmed: 23110467
J Thromb Haemost. 2015 Apr;13(4):580-91
pubmed: 25604127
Blood. 2020 Feb 20;135(8):518-519
pubmed: 32078685
Thromb Haemost. 2017 Apr 3;117(4):671-681
pubmed: 28124063
J Biol Chem. 1983 Jul 10;258(13):8215-22
pubmed: 6553053
J Biol Chem. 2014 Aug 22;289(34):23596-608
pubmed: 24970892
J Biol Chem. 1980 Aug 10;255(15):7281-6
pubmed: 7391081
Science. 1964 Sep 18;145(3638):1310-2
pubmed: 14173416
J Thromb Haemost. 2008 Nov;6(11):1876-83
pubmed: 18761718
Protein Sci. 1995 Mar;4(3):337-60
pubmed: 7795518
Cell Mol Life Sci. 2008 Apr;65(7-8):1220-36
pubmed: 18259688
N Engl J Med. 2018 Jul 26;379(4):352-362
pubmed: 30044938
J Allergy Clin Immunol. 2007 Aug;120(2):416-22
pubmed: 17559913
Front Med (Lausanne). 2018 Jan 25;5:3
pubmed: 29423395
EMBO J. 1997 Aug 15;16(16):4797-805
pubmed: 9305622
Sci Transl Med. 2014 Feb 5;6(222):222ra17
pubmed: 24500405
Biochemistry. 1986 May 6;25(9):2410-7
pubmed: 3521732
Nature. 1964 May 2;202:498-9
pubmed: 14167839
Blood. 2011 Nov 10;118(19):5302-11
pubmed: 21821705
Blood. 1982 Jul;60(1):64-70
pubmed: 6979361
Sci Rep. 2019 Dec 12;9(1):18990
pubmed: 31831842
J Biol Chem. 1985 Feb 10;260(3):1723-9
pubmed: 2578463
Thromb Res. 2016 Apr;140:118-124
pubmed: 26950760
J Thromb Haemost. 2019 May;17(5):759-770
pubmed: 30801944
Front Med (Lausanne). 2018 Apr 17;5:107
pubmed: 29719836
Blood. 1997 Nov 15;90(10):3819-43
pubmed: 9354649
J Exp Med. 1979 Nov 1;150(5):1122-33
pubmed: 501286
J Thromb Haemost. 2016 Aug;14(8):1498-506
pubmed: 27282310
N Engl J Med. 2017 Feb 23;376(8):717-728
pubmed: 28225674
Curr Opin Hematol. 2017 Sep;24(5):411-418
pubmed: 28604413
Biochemistry. 1986 May 6;25(9):2417-24
pubmed: 3636155
Biochemistry. 1996 Nov 12;35(45):14070-6
pubmed: 8916892
Blood Adv. 2018 Mar 13;2(5):549-558
pubmed: 29519898
Curr Opin Struct Biol. 2012 Aug;22(4):421-31
pubmed: 22664096
Res Pract Thromb Haemost. 2018 Jan;2(1):168-173
pubmed: 29354798
J Biol Chem. 1985 Nov 5;260(25):13666-76
pubmed: 3877053
J Thromb Haemost. 2014 Sep;12(9):1513-22
pubmed: 25039405
Biochemistry. 1991 Feb 26;30(8):2056-60
pubmed: 1998667
Immunol Allergy Clin North Am. 2017 Aug;37(3):513-525
pubmed: 28687106
Semin Thromb Hemost. 2017 Nov;43(8):814-826
pubmed: 28346966
Blood. 2017 Mar 16;129(11):1527-1537
pubmed: 28069606
Chem Immunol Allergy. 2014;100:205-13
pubmed: 24925400
J Thromb Haemost. 2019 Dec;17(12):2131-2140
pubmed: 31420909
Sci Rep. 2018 Mar 6;8(1):4080
pubmed: 29511224
Blood. 2018 Apr 26;131(17):1903-1909
pubmed: 29483100
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
J Thromb Haemost. 2019 Jan;17(1):183-194
pubmed: 30394658
Trends Biotechnol. 2011 Nov;29(11):577-85
pubmed: 21726912
Thromb Haemost. 2006 Jun;95(6):1003-10
pubmed: 16732380
Proc Natl Acad Sci U S A. 1979 Mar;76(3):1461-3
pubmed: 286331

Auteurs

Aleksandr Shamanaev (A)

Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA.

Jonas Emsley (J)

Biodiscovery Institute, Centre for Biomedical Science, University of Nottingham, Nottingham, UK.

David Gailani (D)

Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH